2015
Dose Selection of Antithrombin (Recombinant) for a Phase 3 Trial in Early-Onset Preeclampsia [149]
Paidas M, Frieling J, de Jongh J, Drenth H, Streisand J. Dose Selection of Antithrombin (Recombinant) for a Phase 3 Trial in Early-Onset Preeclampsia [149]. Obstetrics And Gynecology 2015, 125: 52s. DOI: 10.1097/01.aog.0000463689.71574.8f.Peer-Reviewed Original ResearchEarly-onset preeclampsiaRecombinant human antithrombinPhase 3 trialPopulation pharmacokinetic modelingHuman antithrombinAntithrombin deficiencyPlasma antithrombinPharmacokinetic modelingHereditary antithrombin deficiencyPopulation pharmacokinetic modelAntithrombin activity levelsDifferent pharmacokinetic propertiesPrior human studiesExpectant managementPerinatal morbidityPregnant patientsLoading doseMaternal administrationPregnant womenContinuous infusionSimilar efficacyClinical studiesPleiotropic effectsAntithrombin treatmentDose selection
2013
347: Recombinant human antithrombin (rhAT) for prevention of venous thromboembolism (VTE) in pregnant patients with hereditary antithrombin deficiency (HD)
Paidas M, Triche E, James A, Ballard T, Lowry S. 347: Recombinant human antithrombin (rhAT) for prevention of venous thromboembolism (VTE) in pregnant patients with hereditary antithrombin deficiency (HD). American Journal Of Obstetrics And Gynecology 2013, 208: s154. DOI: 10.1016/j.ajog.2012.10.512.Peer-Reviewed Original Research